1,487 Shares in Insulet Corporation $PODD Acquired by United Services Automobile Association

Key Points

• United Services Automobile Association acquired 1,487 shares of Insulet Corporation, valued at approximately $385,000, indicating increased institutional interest in the company.
• Insulet reported earnings per share of $1.17 for the last quarter, significantly surpassing analysts' estimates of $0.92, alongside a 32.9% year-over-year revenue growth.
• Several analysts have raised their price targets for Insulet's stock, with the average target now at $335.12, reflecting positive market sentiment following strong performance results.

United Services Automobile Association purchased a new position in Insulet Corporation (NASDAQ:PODD - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,487 shares of the medical instruments supplier's stock, valued at approximately $385,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Larson Financial Group LLC grew its stake in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 81 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet in the 1st quarter worth approximately $26,000. SouthState Corp grew its stake in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 76 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of Insulet in the 1st quarter worth approximately $53,000. Finally, NewEdge Advisors LLC grew its stake in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after buying an additional 64 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Price Performance

Shares of Insulet stock opened at $337.94 on Friday. Insulet Corporation has a one year low of $225.28 and a one year high of $353.50. The stock's fifty day moving average is $310.77 and its 200 day moving average is $291.47. The stock has a market cap of $23.79 billion, a P/E ratio of 102.72, a P/E/G ratio of 2.80 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the prior year, the business posted $0.55 EPS. Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Barclays upped their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Oppenheimer upped their price objective on Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research report on Monday. Truist Financial assumed coverage on Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective on the stock. Finally, Wells Fargo & Company upped their price objective on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.